The goal of this study was to characterize the function of microRNA-27a-3p (miR-27a-3p) in polycystic ovary syndrome (PCOS). miR-27a-3p expression was analyzed in excised granulosa cells (GCs) from 21 patients with PCOS and 12 normal patients undergoing in vitro fertilization cycle treatments and in 17 nontreated cuneiform ovarian resection PCOS samples and 13 control ovarian samples from patients without PCOS. We found that the expression of miR-27a-3p was significantly increased in both excised GCs and the ovaries of patients with PCOS compared with the controls. Insulin treatment of the human granulosa-like tumor cell line (KGN) resulted in decreased downregulated expression of miR-27a-3p, and this effect appeared to be mediated by signal transducer and activator of transcription STAT1 and STAT3. The overexpression of miR-27a-3p in KGN cells inhibited SMAD5, which in turn decreased cell proliferation and promoted cell apoptosis. After KGN cells were stimulated with insulin for 48 hours, there was increased expression of SMAD5 protein and decreased apoptosis. Additionally, knockdown/overexpression of SMAD5 in KGN cells reduced/increased cell number and promoted/inhibited cell apoptosis. Insulinstimulated primary GCs isolated from patients with PCOS, in contrast to normal GCs or KGN cells, did not exhibit decreased miR-27a-3p expression. The differences in the expression levels in KGN cells and human PCOS GCs are likely explained by increased miR-27a-3p expression in the GCs caused by insulin resistance in PCOS. Taken together, our data provided evidence for a functional role of miR-27a-3p in the GCs' dysfunction that occurs in patients with PCOS. (Endocrinology 159: 297-309, 2018) P olycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders in women of reproductive age and is characterized by hyperandrogenemia with arrest of follicle growth and ovulatory dysfunction (1-3). It has been reported that 75% of infertile women may suffer from PCOS worldwide
. The majority of patients with PCOS exhibit insulin resistance, leading to hyperinsulinemia and increased risk for type 2 diabetes mellitus and cardiovascular disease (5) . Patients with PCOS often have elevated levels of ovarian androgens, and about 50% of patients show elevated serum dehidroepiandorstendione sufate, potentially of adrenal origin (6) . Several genetic and environmental factors have been reported to contribute to the development of PCOS (2, 7) . However, the underlying molecular mechanism leading to PCOS remains unclear.
Granulosa cells (GCs) play an important role during folliculogenesis. Proliferating GCs provide a suitable microenvironment for follicle growth initiation, oocyte maturation, and atresia (8) . Dysfunction of GCs in patients with PCOS, including decreased proliferation, increased apoptosis, or unbalanced hormone production, may contribute to abnormal folliculogenesis (9, 10) .
MicroRNAs (miRNAs) are 21-to 25-nucleotide noncoding RNAs that are able to posttranscriptionally regulate gene expression (11) . These miRNAs function as important regulators of various physiological and pathological processes, such as development, cell proliferation, differentiation, migration, and apoptosis (12) (13) (14) . It has been suggested that ovarian miRNAs may play a role in PCOS (15, 16) . McCallie et al. (17) showed that the expression levels of six miRNAs, including hsa-let-7a, hsa-miR-19a, hsa-miR-19b, hsa-miR-24, hsa-miR-92, and hsa-miR-93, were noticeably downregulated in PCOS blastocysts compared with controls. Similarly, Roth et al. (18) reported decreased expression of miR-132 and miR-320 in the follicular fluid of patients with PCOS. In addition, several serum miRNAs differentially expressed in patients with PCOS were suggested to play key roles in pathological insulin signaling, inflammation, and hormone secretion (15) . Although the abnormal expression of miRNAs directly affects follicle development and the normal physiological function of ovaries, the role of miRNAs in PCOS GCs remains unknown.
Our recent profiling data analysis predicted that novel miRNAs may be involved in the pathophysiology of PCOS (3) . The recent advancements in high-throughput profiling and sequencing provide a comprehensive tool to understand the various signaling pathways and molecular networks involved in the etiology and pathophysiology of PCOS. Thus, our next goal was to dissect the functional role of individual miRNA participating in the pathology. In this study, we focused on the functional characterization of miRNA-27a-3p (miR-27a-3p) expression in ovaries and GCs from patients with PCOS. Additionally, we analyzed miR-27a-3p function using a human granulosa tumor-like cell line to explore the mechanistic role of miR-27a-3p in the dysfunction of GCs.
Materials and Methods

Human GCs
We analyzed GCs excised from a total of 42 donor patients (healthy control patients, n = 17 [quantitative polymerase chain reaction (qPCR) analysis, n = 13; in vitro, n = 4] and patients with PCOS, n = 25 [qPCR analysis, n = 21; in vitro, n = 4]) undergoing in vitro fertilization (IVF) stimulation cycles with the classical standard protocol of gonadotropin-releasing hormone (GnRH) antagonist (Cetrotide) 0.25 mg subcutaneously (s.c.) plus recombinant follicle-stimulating hormone 150 IU s.c. plus ovulation peak induced by 0.2 mg (Gonapeptyl) daily Ferring Pharmaceuticals s.c. GnRH agonist (19) . The revised criteria from the Rotterdam European Society of Human Reproduction and Embryology and American Society for Reproductive Medicine (17, 20) were used for diagnosis of PCOS. GCs were obtained by follicular fluid aspiration. After oocyte removal, follicular fluid containing GCs were pooled and centrifuged at 250 3 g for 10 minutes. The fraction containing the GCs was carefully aspirated, transferred to a new centrifuge tube, resuspended, washed in phosphate-buffered saline (PBS; Gibco), and then centrifuged at 250 3 g for 5 minutes. GC pellets were lysed with TRIsure (Bioline, UK) for total RNA extraction or resuspended in culture medium for in vitro studies. Only GCs from follicles with mature oocytes were included in this study. The local Human Investigation Ethics Committee at the Medical University of Bialystok, Bialystok, Poland, approved the study (license number R-I-002/146/2016). Written informed consent was obtained from all patients/donors before the study.
Human ovarian samples
We examined ovaries from a total number of 30 patients (normal healthy control patients, n = 13, and patients with PCOS, n = 17). This study group included patients of reproductive age, with PCOS diagnosed according to the European Society of Human Reproduction and Embryology and American Society for Reproductive Medicine criteria (20) . The patients with PCOS qualified for an ovarian cuneiform resection by laparoscopy due to a lack of ovarian response to multiple (three to six) cycles of clomiphene citrate stimulation or treatment with pituitary gonadotropin hormones. The control ovarian group (n = 13) consisted of patients of reproductive age who did not meet the PCOS diagnostic criteria (20) but who had undergone surgical procedures for other reasons, such as small ovarian cysts, fibroids, or chronic pelvic pain, or for diagnostic infertility laparoscopy that may have required a biopsy of healthy tissues or lesion removal with a healthy tissue margin. The patient exclusion criteria for both groups were as follows: ovarian, adrenal, endometrial, cervical, and breast neoplasms, pelvic endometriosis, congenital adrenal hyperplasia, clinically and/or laboratory-confirmed endocrine disease (thyroid dysfunction, acromegaly, gigantism, or Cushing disease), diabetes type I or II, hyperprolactinemia, and unexplained vaginal bleeding. Ovarian cuneiform resection samples were collected during laparoscopic surgery, protected against RNA degradation by mixing with RNA later (Life Technologies), snap-frozen in liquid nitrogen, and stored at -80°C until analyzed. The local Human Investigation Ethics Committee at the Medical University of Poznan, Poznan, Poland, approved the study (license number 955/16). Written informed consent was obtained from all patients/donors before the study.
Total RNA isolation
Total RNA was isolated from human ovaries and GCs using a Trizol-based standard extraction protocol according to the manufacturer's instructions (Life Technologies). The total RNA concentration was quantified using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific).
Reverse transcription and real-time qPCR
For normal and PCOS ovarian/GC total RNA samples, reverse transcription (RT) was performed with the SensiFAS cDNA Synthesis Kit (Bioline). Prior to complementary DNA synthesis, 1 mg of total RNA was incubated with 1 mL of DNase I according to the manufacturer's protocol (Invitrogen). RT was performed in a thermal cycler using the following conditions: 25°C for 10 minutes, 42°C for 15 minutes, 48°C for 15 minutes (an additional step for highly structured RNA), 85°C for 5 minutes, and then 4°C. Next, qPCR was performed with the DyNAmo HS SYBR Green qPCR Kit (Thermo Fisher Scientific) and the primers indicated in Supplemental Table 1 using the CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Following an initial denaturation at 95°C for 10 minutes, 40 cycles of PCR amplification were performed of 95°C for 10 seconds, 58°C to 60°C for 20 seconds, and 72°C for 15 seconds.
For human granulosa-like tumor cell line (KGN) and HeLa cells, RT was performed with the Complementary DNA Synthesis Kit (Thermo Fisher Scientific) using the following conditions: 42°C for 90 minutes and 95°C for 5 minutes followed by a hold at 4°C. Next, complementary DNA was amplified in a Roche LightCycler 480 system using SYBR Green Master Mix Reagent (Roche, Switzerland). Cycling conditions were as follows: denaturation for 10 minutes at 95°C followed by 40 cycles of 10 seconds at 95°C, 10 seconds at 60°C, and 10 seconds at 72°C.
The specificity of qPCR amplification was verified by performing a melting curve analysis and agarose gel electrophoresis. Relative gene expression was calculated by the efficiency-corrected DD threshold cycle method, normalized to the index (geometric mean) of four housekeeping genes: cyclophilin A, b-actin, b-glucuronidase, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Each sample in every group was measured in duplicate.
RT and qPCR to measure miRNA expression RT was performed with the TaqMan MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific) according to the manufacturer's protocol in a thermal cycler using the following conditions: 16°C for 30 minutes, 42°C for 30 minutes, 85°C for 5 minutes, and then 4°C. The miRNA primers/probes used in this study were purchased commercially (Thermo Fisher Scientific) and are shown in Supplemental LightCycler 480 system using SYBR Green Master Mix Reagent with the following conditions: denaturation for 10 minutes at 95°C followed by 40 cycles of 10 seconds at 95°C, 10 seconds at 60°C, and 10 seconds at 72°C. Relative miRNA expression was calculated by the efficiency-corrected DD threshold cycle method and was normalized to the endogenous control U6 small nuclear RNA. Each sample in every group was measured in duplicate.
Cell culture
For in vitro studies, we used human primary GCs from patients with PCOS and normal healthy patents, as well as a steroidogenic human granulosa-like tumor cell line, KGN (21) . GCs were obtained from women with PCOS (n = 4) and healthy controls (n = 4) undergoing IVF treatment. After oocyte removal, samples of follicular fluid containing GCs were sedimented for 30 minuttes. The fraction with GCs was carefully transferred to a new tube and resuspended in culture medium [Dulbecco's modified Eagle medium (DMEM)/F12 medium (Sigma) with 10% fetal bovine serum (Gibco) and 1% antibiotics (100 U/mL penicillin and 100 mg/mL streptomycin; Sigma)]. KGN cells are undifferentiated and maintain the physiological characteristics of ovarian cells, with normal expression of the functional follicle-stimulating hormone receptor and CYP19A1 (21) . KGN cells were grown in DMEM/F12 supplemented with 10% fetal bovine serum and 1% antibiotics and cultured at 37°C under 5% CO 2 . HeLa cells (ATCC CCL-2) were grown in DMEM/high glucose (Sigma) supplemented with 10% fetal bovine serum and grown under the same culture conditions described previously.
Cells were equally distributed onto a 12-well plate. After 12 hours of incubation with full medium, cells were rinsed with PBS and serum-starved for 12 hours [DMEM/F12 medium with 0.5% charcoal-stripped fetal bovine serum]. Next, the medium was exchanged for fresh medium with stimulation of 100, 10, or 1 ng/mL insulin (Sigma), and full medium was used as a positive control. Cells were treated for 24 hours, rinsed with PBS, and then collected with the TRI Reagent Solution (Thermo Fisher Scientific).
KGN cells or primary GCs from patients with PCOS and normal healthy control patients were plated in six-well plates at 2 3 10 5 per well. After starving for 12 hours, the cells were treated without (0) or with insulin at concentrations of 1, 10, and 100 ng/mL for 24 hours to test the expression of miR-27a-3p (for both primary GCs and KGN cells) or 48 hours to test the protein expression level of SMAD5 (for KGN cells).
Plasmids
To experimentally determine if miR-27a-3p targets SMAD5, both the wild-type (5 0 -acuuugaguacagauacugugag-3 0 ) and mutated (5 0 -acuuugaguacagaugacgcaag-3 0 ) 3 0 -untranslated regions (UTRs) of the SMAD5 gene were cloned into the psi-CHECK-2 dual luciferase reporter vector (Promega) using NotI and XhoI restriction sites. To study the effect of signal transducer and activator of transcription (STAT)1 and STAT3 on the expression of miR-27a-3p, the coding sequence of the STAT1 gene was cloned into the eukaryotic expression plasmid pEGFP-C1. To assess the effect of SMAD5 overexpression on KGN cells, we cloned the coding sequence of SMAD5 into the eukaryotic expression plasmid pCDNA3.1. All generated constructs were confirmed by sequencing.
Transient transfection and luciferase activity assay
KGN and/or HeLa cells were transfected with miRNA mimics or an miRNA-negative control (miR-NC) using Lipofectamine 3000 (Invitrogen) following the manufacturer's protocol. miRNA mimics and miR-NC were chemically synthesized (GenePharma, Shanghai, China). Briefly, the day before transfection, cells were plated with normal growth medium and were 70% to 80% confluent at the time of transfection. The time of the start of transfection was considered time 0.
For reporter assays, HeLa cells were transiently transfected with reporter constructs together with miRNA mimics and miR-NC. Cell extracts were prepared 48 hours after transfection, and the ratio of Renilla/firefly luciferase was measured with the Dual-Luciferase Reporter Assay System (Promega).
Cell proliferation
Cell proliferation was measured with the Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology, China). Cells were seeded into 96-well plates at 1 3 10 4 cells per well and cultured in growth medium. After stimulation, 10 mL of the CCK-8 solution was added to each well and then incubated for 2 hours. The cell numbers were measured in a PowerWave HT Microplate Spectrophotometer (BioTek) by measuring the absorbance at a wavelength of optical density 450 nm.
Hormone analysis
The culture medium was collected and the estradiol (E 2 ) and progesterone (P 4 ) concentrations were measured. The measurements were performed by radioimmunoassay by the Institute of Beijing North Biotechnology. Both the inter-and intravariation of the E 2 and P 4 assays were below 10%.
Cell apoptosis analysis
Cell apoptosis was analyzed by annexin V/propidium iodide (PI) staining. After stimulation, cells were washed twice with icecold PBS solution and resuspended in 100 mL of 13 annexin binding buffer with 5 mL of annexin V-FITC (Sigma) and 10 mL of PI (Sigma). The cells were incubated for 15 minutes at room temperature in the dark and were then subjected to flow cytometric analysis using FACSCalibur (Becton Dickinson). The data were analyzed by Flowjo software.
Cell cycle analysis
For cell cycle analysis, cells were harvested after treatment and then fixed in 70% ethanol at 4°C overnight, permeabilized, and stained with PI. After incubation for 15 minutes, 400 mL 13 of binding buffer was added per sample, and the mixture was filtered through a 200-mesh nylon net prior to cell fluorescence measurement using FACSCalibur. Data were analyzed by Flowjo software.
Western blotting
Cells were rinsed with ice-cold PBS, and then the protein was extracted using the radioimmunoprecipitation assay method. Protein samples were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and then transferred to a polyvinylidene fluoride (PVDF) membrane as described previously (22) . After washing, the membranes were incubated with antibodies. Finally, the films were scanned and quantified using ImageJ software.
Microarray data
The expression of SMAD5 in PCOS GCs was mined from the public data set GSE34526 (www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?acc=GSE34526).
Statistical analysis
The results are presented as the means 6 standard error of the mean. Statistical significance was assessed by the twotailed Student t test using the GraphPad Prism 5 software. A P value ,0.05 was considered statistically significant.
Results
Changes in miR-27a-3p expression in PCOS ovaries and GCs
Using data from the published database (3) of the 59 known miRNAs differentially expressed in PCOS vs control GCs (fold change .2 and P , 0.05), 21 miRNAs were upregulated and 38 were downregulated in PCOS GCs. We found that the upregulated miRNAs miR-27a-3p and miR-27a-5p correlated with increased serum testosterone in GCs from PCOS (Supplemental Table 2 ). To validate the miRNA microarray results, we performed real-time qPCR analysis on samples from nontreated healthy controls (n = 13) and patients with PCOS (n = 17). Interestingly, miR-27a-3p was significantly upregulated in both GCs and ovaries from patients with PCOS, but no statistically significant changes were observed for miR27a-5p (Fig. 1A-1D ). miR-27a-3p is located on chromosome 8 in mice and chromosome 19 in humans and is proximal to two other miRNAs, miR-23a and miR-24-2. We also checked the expression of these two miRNAs, but no significant changes in miR-24-2 and miR-23a expression were observed in PCOS GCs and ovaries compared with the level of expression in the controls (Fig. 1E-1H ). The hormonal treatment in the IVF protocol used for both the control patients and patients with PCOS from whom the GCs were excised likely contributed to the observed identical miRNA expression patterns of the nontreated PCOS and control ovary miRNAs (Fig. 1A-1H ). The characteristics of the participants are presented in Table 1 .
Insulin induced the downregulation of miR-27a-3p expression mediated by STAT1 and STAT3 in human granulosa-like tumor cell line (KGN)
Hyperinsulinemia is one of the most common features of PCOS. We hypothesized that miR-27a-3p may be regulated by insulin. We performed qPCR using KGN cells (21) stimulated with insulin to assess the expression of miR-27a-3p. The qPCR results showed approximately 0.40-fold and 0.50-fold decreases in the levels of miR27a-3p after 24-hour treatment with 10 and 100 ng/mL insulin, respectively (Fig. 2A) . To determine the underlying mechanism of how insulin led to the downregulation of miR-27a-3p, we analyzed the region of 2000 nucleotides upstream of miR-27a-3p using the JASPAR database. Among the potential binding transcription factors (TFs), two TFs (STAT1 and STAT3) were selected based on their multiple conserved predicted binding sites and their known roles in proliferation and apoptosis (Fig. 2B) . To clarify the effects of the two TFs, STAT1 and STAT3, on the expression of miR-27a-3p, we transfected a STAT1-overexpression vector (pEGFP-STAT1) and a control vector, pEGFP, into KGN cells. The qPCR results showed a significant decrease of miR-27a-3p in the STAT1-overexpressed cells compared with controls (Fig. 2C) . To explore whether these two TFs are regulated by Figure 1 . Expression of miR-27a-3p and other miRNAs in human GCs of nontreated and treated normal healthy patients and patients with PCOS. (A-H) The expression of miR-27a-3p, miR-27a-5p, miR-23a, and miR-24-2 in excised GCs of 12 healthy control patients and 21 patients with PCOS undergoing IVF treatment and 13 non-PCOS cuneiform ovarian resections and nontreated 17 PCOS. miR-27a-3p expression in (A) GCs and (B) ovaries in the PCOS group compared with the control group. (C and D) miR-27a-5p, (E and F) miR-23a, and (G and H) miR-24-2 expression in both groups. **P , 0.01. OV, ovarian. doi: 10.1210/en.2017-00219 https://academic.oup.com/endoinsulin, we measured the protein levels in KGN cells treated with insulin for 48 hours and found that STAT1 and STAT3 were obviously decreased in the insulintreated cells and that this effect was dose-independent ( Fig. 2D-2F ). These data demonstrated that miR-27a-3p could be regulated by insulin and that this effect may be mediated by STAT1 and STAT3.
Overexpression of miR-27a-3p decreased GC proliferation and promoted apoptosis in KGN cells
To assess the functional role of miR-27a-3p in GCs, we transfected either miR-27a-3p mimics or miR-NC into the KGN cell line. The expression of miR-27a-3p in cells after transfection was measured by qPCR analysis. Transfection with miR-27a-3p mimics increased intracellular miR-27a-3p levels by approximately 1700-fold (Fig. 3A) . Recent studies have reported that differential expression of miRNAs is involved in hormone secretion and proliferation in GCs (23) (24) (25) . Next, we studied the production of (17) E 2 and P 4 by KGN cells in response to the overexpression of miR-27a-3p. The overexpression of miR-27a-3p had no effect on E 2 and P 4 production in GCs (Supplemental Fig. 1A ). Using the CCK-8 assay, we observed a significantly reduced number of GCs 48 hours after transfection of miR-27a-3p mimics into GCs (P , 0.05) (Fig. 3B ). To further demonstrate how miR-27a-3p affects GCs growth, we examined the apoptotic rate and cell cycle in KGN. Using annexin V-FITC and PI staining and flow cytometry 48 hours posttransfection, we observed that the overexpression of miR-27a-3p significantly increased the apoptotic rate of KGN cells (P , 0.05) ( Fig. 3C; Supplemental Fig. 1B) . Using PI staining and flow cytometry analysis, we observed no changes in cell numbers of G0/G1 phase and G2/M phase (Fig. 3D) . Also, we found that the protein expression levels of proliferating cell nuclear antigen (PCNA) and the messenger RNA (mRNA) expression level of cell cycle-related genes (CDK6, cyclin D1, and cyclin E) were not altered ( Fig. 3E and 3F ). All of these data indicated that miR27a-3p decreased the number of GCs by promoting cell apoptosis.
SMAD5 is a potential target of miR-27a-3p in KGN cells
To study the effects of miR-27a-3p on apoptotic target mRNAs, seed sequence-based predictions were performed in miRDB and TargetScan. Among the candidate targets of miR-27a-3p, we found that the SMAD5 gene seemed an appropriate candidate, because it is involved in cell apoptosis (26) . The 3 0 -UTR of SMAD5 mRNA contains an evolutionarily conserved miR-27a-3p putative binding site in vertebrates (Supplemental Fig. 1C ). To determine whether SMAD5 is a true target of miR-27a-3p, we constructed dual luciferase reporter vectors containing the wild-type 3 0 -UTR of SMAD5, as well as a mutant form of the miR-27a-3p seed sites (Supplemental Fig. 1D ). HeLa cells were cotransfected with the reporter plasmids and miR-27a-3p mimics or miR-NC and harvested 48 hours after transfection and assayed for dual luciferase activity. As shown in Fig. 3G , the luciferase activity from the wild-type SMAD5 3 0 -UTR was reduced by 40% in the presence of the miR-27a-3p mimics. However, the mutant form of the seeding site abolished the silencing effects of miR-27a-3p on SMAD5 3 0 -UTR reporter activity. These results indicated that miR-27a-3p suppresses SMAD5 expression by directly binding to its 3 0 -UTR. To validate that the SMAD5 gene is a target of miR27a-3p, KGN cells were transfected with miR-27a-3p mimics or miR-NC. Next, qPCR and Western blot analysis were performed, and the results revealed that the expression of SMAD5 mRNA (Fig. 3H) and protein (Fig. 3I ) in KGN cells was significantly lower in miR-27a-3p transfected KGN compared with the control cells. Thus, our results demonstrated that the SMAD5 gene is a miR-27a-3p target and that miR-27a-3p regulates SMAD5 gene expression both at the transcriptional level and the posttranscriptional level. Additionally, we measured SMAD5 mRNA expression in the PCOS GCs and ovarian samples and observed that SMAD5 was significantly downregulated in the PCOS group ( Fig. 3J and 3K) . Interestingly, the expression profiling of human miRNAs from the public database (27) showed a similar result (Fig. 3L) . Taken together, the SMAD5 gene seemed a likely potential target of miR-27a-3p.
Knockdown/overexpression of SMAD5 reduced/increased apoptosis in KGN cells
We knocked down SMAD5 expression by using small interfering RNA (si-SMAD5). The expression of SMAD5 mRNA (Fig. 4A) and protein (Fig. 4B) was decreased in cells transfected with si-SMAD5 for 48 hours compared with the expression levels of the controls. Next, we measured the production of E 2 and P 4 by KGN cells and found that knockdown of SMAD5 had no effect on E 2 and P 4 production in KGN cells (Supplemental Fig. 2A  and 2B) . By using the CCK-8 assay, we observed a significantly reduced number of KGN cells 24 hours after transfection with si-SMAD5 (P , 0.05) (Fig. 4C) . Using annexin V-FITC and PI staining and flow cytometry 48 hours posttransfection, we observed that knockdown of SMAD5 significantly increased the apoptotic rate of KGN cells (P , 0.05) ( Fig. 4D; Supplemental Fig. 2D ). Using PI staining and flow cytometry analysis, we observed no changes in the cell numbers of G0/G1 and G2/ M phases (Supplemental Fig. 2C) . Conversely, when we overexpressed SMAD5 in KGN cells, we observed an increased cell number ( Fig. 4G; Supplemental Fig. 2H ) and reduced apoptosis rate ( Fig. 4H; Supplemental   Fig. 2I ) but no obvious change in the cell cycle (Supplemental Fig. 2G ) or the hormone secretion of E 2 and P 4 ( Fig. 4E and 4F; Supplemental Fig. 2E and 2F ). All The mRNA expression level of SMAD5 in PCOS GCs from public database. GAPDH was used to normalize the expression level. *P , 0.05; **P , 0.01; ***P , 0.001. OD, optical density; OV, ovarian; mut, mutant; S, synthesis phase.
of these data showed that SMAD5 knockdown decreased the number of KGN cells by promoting cell apoptosis, which is similar to the effects of miR-27a-3p overexpression.
Insulin induced the upregulation of SMAD5 protein level and reduced apoptosis in KGN cells
We showed that miR-27a-3p was regulated by insulin and promoted apoptosis in KGN cells. There are several reports that insulin could promote KGN cell proliferation (28, 29) . Therefore, we next explored the proliferation and apoptotic effects of insulin on KGN cells. We applied an insulin concentration of 100 ng/mL for 48 hours and observed a significantly increased number of GCs by CCK-8 assay (P , 0.05) (Fig. 5A ) and inhibited apoptosis in KGN cells ( Fig. 5B; Supplemental Fig. 3A) . Additionally, the expression of SMAD5 was increased after the insulin treatment ( Fig. 5C and 5D ). These data further demonstrated that miR-27a-3p promoted apoptosis in KGN cells by targeting SMAD5. Insulin treatment of GCs derived from normal patients and patients with PCOS GCs from patients with PCOS and normal healthy patients were stimulated with varying doses of insulin to assess the effects on the expression of miR-27a-3p. qPCR analysis showed no significant changes in the PCOS GCs after insulin treatment vs nontreated PCOS GCs, but miR-27a-3p levels were higher compared with the GCs from normal healthy women (Fig. 6 ).
Discussion
A growing number of studies suggest that miR-27a-3p plays important functions in various physiological and pathological processes (30) (31) (32) . Zhou et al. (33) found that miR-27a-3p targets BTG2 in gastric cancer and plays a role as a growth-promoting and antiapoptotic factor. Another study reported that miR-27a-3p can induce apoptosis in human prostate cancer cells (34) . These proapoptotic or antiapoptotic properties of miR27a-3p suggested that miR-27a-3p may play different functions in different physiological states and pathological conditions according to the environmental context. GC apoptosis can induce follicular atresia, which leads to oocyte maturation and follicular developmental disorder. A high rate of apoptosis in GCs can prevent the conversion of androgen to estrogen, causing local hormone changes within the follicle and disturbing normal follicular development (35, 36) . Our data showed that the level of miR-27a-3p was increased/upregulated in GCs of patients with PCOS and that overexpression of miR-27a-3p in KGN cells inhibited proliferation and promoted apoptosis. Additionally, we identified SMAD5, previously reported to regulate cell apoptosis, as a potential target of miR-27a-3p (37, 38) . We investigated this by Western blot, luciferase reporter assay, and flow cytometry. Our results suggest that miR-27a-3p may target SMAD5 to promote apoptosis in KGN cells, which may suggest a potential role in PCOS pathogenesis due to GC apoptosis.
An earlier report showed that miR-23a and miR-27a promote human GC apoptosis by targeting SMAD5 (26) . However, our results differ from those results in several ways. Nie et al. (26) found that miR-27a-3p is upregulated in patients with premature ovarian failure, but patients with PCOS were excluded from their analysis. In our study, we focused on patients with PCOS. We found that miR-27a-3p was upregulated and SMAD5 was downregulated in PCOS GCs. In contrast to normal GCs or KGN cells, due to insulin resistance, the expression of miR-27a-3p in PCOS GCs was not affected by insulin. Normal GCs or KGN cells responded to insulin treatment with decreased expression of miR-27a-3p and increased expression of SMAD5, and both these changes decreased apoptosis. Our data also showed that insulin levels in KGN cells downregulated the expression of miR-27a-3p and that this downregulation occurred via STAT1 and STAT3, which was not reported previously.
GCs are the main source of steroidogenesis, including production of E 2 and P 4 . Gonadal steroids play key roles in ovarian follicular development, oocyte maturation, and ovulation (39) . Some miRNAs were recently reported to influence steroid hormone release by ovarian GCs (40, 41) . In the current study, we observed that miR-27a-3p overexpression in KGN cells had no substantial effect on E 2 and P 4 secretion. Thus, miR-27a-3p may use a strategy other than hormone secretion to affect GC function.
It is well known that insulin plays a key role in the regulation of ovarian function and stimulates the proliferation and hormone production of GCs (22, 42) . Several miRNAs have been reported to be regulated by insulin in PCOS (29) . Jiang et al. (28) reported that high concentrations of insulin induced the upregulation of miR-93, stimulated KGN cell proliferation, and reduced CDKN1A expression in PCOS. Xiang et al. (29) observed that insulin treatment in KGN cells inhibited miR-483 and promoted IGF1 and cell proliferation. In this work, we found that insulin could downregulate the expression of miR-27a-3p and inhibit apoptosis in KGN cells. The mechanism explaining the changes mediated by insulin in apoptosis and the effects on the TFs upstream of miR-27a-3p, STAT1 and STAT3, require further study. Additionally, further clinical investigations of miRNA expression for a large group of patients with PCOS are needed.
Hyperandrogenism is a key endocrine characteristic of patients with PCOS (43) . Androgens are mainly produced in adrenal glands and ovaries, but the hyperandrogenism of PCOS is closely related to the ovaries (44) . Androgens via the androgen receptor induced the expression of miR-125b in mouse GCs, KGN cells, and GCs from women undergoing IVF (45) . Similarly, miR27a-3p expression is regulated by androgen in prostate cancer, both transcriptionally and posttranscriptionally (46) , Another study demonstrated activity of miR-27a-3p as an androgen-induced tumor suppressor, targeting MAP2K4 in prostate cancer (34) . Although miR-27a-3p has been proposed to be an androgen response miRNA, this analysis was not within the scope of this study.
Taken together, the first part of our study demonstrated significantly high levels of miR-27a-3p expression in PCOS GCs and ovary. The last part of the study showed the role of miR-27a-3p in the downregulation of SMAD5 and induction of apoptosis. However, there were contradictions between the findings in the first and last part of this study, as insulin downregulated miR-27a-3p expression in KGN cells, but samples from patients with PCOS presented with higher levels of insulin and higher levels of miR-27a-3p expression. Thus the question is, if insulin decreased miR-27a-3p expression in GCs, how did the increased insulin level increase miR-27a-3p expression? Insulin-stimulated primary GCs isolated from patients with PCOS, in contrast to normal GCs or human ovarian granulosa-like tumor cells (KGN cell line), did not respond to decreased miR-27a-3p expression. This lack of decreased miR-27a-3p expression in GCs of patients with PCOS displaying increased insulin levels could be explained by the insulin resistance of GCs. In the regulation of miR-27a-3p expression, KGN cells exhibited characteristics of normal human GCs. Although the KGN cell line is a useful model to understand the regulation of steroidogenesis, cell growth, and apoptosis in human GCs (21), it might not be a good model to study GC functions in the context of insulin resistance or hyperinsulinemia. Figure 6 . Expression of miR-27a-3p in primary GCs treated with insulin. The expression level of miR-27a-3p in GCs from patients with PCOS and normal healthy patients treated with different doses of insulin. **P , 0.01; ***P , 0.001. Table   Peptide 
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